Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Bevacizumab with or without Chemotherapy in Pre-treated Non-Squamous NSCLC
NCT07134413Phase 2Not yet recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2025
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Guangdong Association of Clinical Trials. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07134413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134413.